Sylvain Ladoire

18.4k total citations · 2 hit papers
186 papers, 7.5k citations indexed

About

Sylvain Ladoire is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sylvain Ladoire has authored 186 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 75 papers in Pulmonary and Respiratory Medicine and 44 papers in Surgery. Recurrent topics in Sylvain Ladoire's work include Cancer Immunotherapy and Biomarkers (43 papers), Renal cell carcinoma treatment (24 papers) and Breast Cancer Treatment Studies (23 papers). Sylvain Ladoire is often cited by papers focused on Cancer Immunotherapy and Biomarkers (43 papers), Renal cell carcinoma treatment (24 papers) and Breast Cancer Treatment Studies (23 papers). Sylvain Ladoire collaborates with scholars based in France, United States and Italy. Sylvain Ladoire's co-authors include François Ghiringhelli, François Martin, Lionel Apétoh, Cédric Rébé, Grégoire Mignot, Bruno Chauffert, Julie Vincent, Fanny Chalmin, Laurence Zitvogel and Mélanie Bruchard and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sylvain Ladoire

179 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

2010 969 citations Julie Vincent, Grégoire Mignot et al. Cancer Research profile →
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 968 citations François Ghiringhelli, Sylvain Ladoire et al. profile →

Peers

Sylvain Ladoire

ONCOL

IMMUN

PRM

Brendan D. Curti United States

Bo Zhu China

Philippe Wind France

Marco Alifano France

David S. Schrump United States

Franco Silvestris Italy

Hana Algül Germany

Michael von Bergwelt‐Baildon Germany

Patrick Micke Sweden

David J. Pinato United Kingdom

Brendan D. Curti United States

Sylvain Ladoire

3.4k ×0.8

ONCOL

2.4k ×0.7

IMMUN

2.1k ×1.5

1.9k ×1.6

PRM

935 ×1.1

Citations per year, relative to Sylvain Ladoire Sylvain Ladoire (= 1×) peers Brendan D. Curti

Countries citing papers authored by Sylvain Ladoire

Since Specialization

Citations

This map shows the geographic impact of Sylvain Ladoire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Ladoire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Ladoire more than expected).

Fields of papers citing papers by Sylvain Ladoire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Ladoire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Ladoire. The network helps show where Sylvain Ladoire may publish in the future.

Co-authorship network of co-authors of Sylvain Ladoire

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Ladoire. A scholar is included among the top collaborators of Sylvain Ladoire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Ladoire. Sylvain Ladoire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laurentiis, Michelino De, Xin Hu, Marina Elena Cazzaniga, et al.. (2025). 489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial. Annals of Oncology. 36. S380–S381. 1 indexed citations

Spehner, Laurie, Fabrice André, Elsa Curtit, et al.. (2025). Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. Breast Cancer Research. 27(1). 19–19. 2 indexed citations

Baboudjian, Michaël, Charles Dariane, Gaëlle Fromont, et al.. (2024). Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review. European Urology Oncology. 7(6). 1228–1245. 3 indexed citations

Bertaut, Aurélie, Sylvain Ladoire, Isabelle Desmoulins, et al.. (2024). HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity. Cancers. 16(11). 2009–2009. 1 indexed citations

Bergstrom, Erik N., Ammal Abbasi, Marcos Díaz‐Gay, et al.. (2024). Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides. Journal of Clinical Oncology. 42(30). 3550–3560. 17 indexed citations

Bidard, François‐Clément, Nicolas Kiavué, William Jacot, et al.. (2023). Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology. 42(4). 383–389. 28 indexed citations

Arnould, Laurent, Françoise Beltjens, Didier Mayeur, et al.. (2023). Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 30(6). 997–1007. 8 indexed citations

Ladoire, Sylvain, et al.. (2023). Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma. Journal of Clinical Medicine. 12(8). 2916–2916. 5 indexed citations

Ladoire, Sylvain, Cédric Rébé, & François Ghiringhelli. (2022). Associating Immunotherapy and Targeted Therapies: Facts and Hopes. Clinical Cancer Research. 29(7). 1183–1193. 6 indexed citations

10.

MacGrogan, Gaëtan, Aurélie Bertaut, Sylvain Ladoire, et al.. (2021). Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Modern Pathology. 34(7). 1282–1296. 23 indexed citations

11.

Beltjens, Françoise, Aurélie Bertaut, Corentin Richard, et al.. (2021). ER−/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple‐negative breast cancer. International Journal of Cancer. 149(1). 200–213. 17 indexed citations

12.

Gross‐Goupil, Marine, Aude Fléchon, Loı̈c Mourey, et al.. (2020). 722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study. Annals of Oncology. 31. S566–S567. 4 indexed citations

13.

Coutant, Charles, Jean‐Marc Riedinger, Sylvain Ladoire, et al.. (2019). Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer. European Journal of Radiology. 113. 81–88. 11 indexed citations

14.

Humblin, Étienne, Marion Thibaudin, Fanny Chalmin, et al.. (2017). IRF8-dependent molecular complexes control the Th9 transcriptional program. Nature Communications. 8(1). 2085–2085. 48 indexed citations

15.

Limagne, Emeric, Romain Euvrard, Marion Thibaudin, et al.. (2016). Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen. Cancer Research. 76(18). 5241–5252. 213 indexed citations

16.

Berger, Hélène, Frédérique Végran, Federica Gilardi, et al.. (2013). SOCS3 Transactivation by PPARγ Prevents IL-17–Driven Cancer Growth. Cancer Research. 73(12). 3578–3590. 47 indexed citations

17.

Ladoire, Sylvain, Dalil Hannani, Marie Vétizou, et al.. (2013). Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. Antioxidants and Redox Signaling. 20(7). 1098–1116. 37 indexed citations

18.

Vincent, Julie, Grégoire Mignot, Fanny Chalmin, et al.. (2010). 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity. Cancer Research. 70(8). 3052–3061. 969 indexed citations breakdown →

19.

Guiu, Boris, et al.. (2010). Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anti-Cancer Drugs. 21(6). 656–661. 18 indexed citations

20.

Quenot, Jean‐Pierre, Sylvain Ladoire, Jean‐Marc Doise, et al.. (2007). Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia*. Critical Care Medicine. 35(9). 2031–2036. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact